edaravone has been researched along with Muscular Atrophy, Spinal in 2 studies
Muscular Atrophy, Spinal: A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, S | 1 |
| Funato, M | 1 |
| Ohuchi, K | 1 |
| Kameyama, T | 1 |
| Inagaki, S | 1 |
| Seki, J | 1 |
| Kawase, C | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Kaneko, H | 1 |
| Hara, H | 1 |
| Kiernan, MC | 1 |
2 other studies available for edaravone and Muscular Atrophy, Spinal
| Article | Year |
|---|---|
Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model.
Topics: Animals; Antipyrine; Apoptosis; Disease Models, Animal; Edaravone; Fibroblasts; Humans; Induced Plur | 2017 |
Motor neuron disease in 2017: Progress towards therapy in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Benzamides; Edaravone; Humans; Muscular Atrophy, Spinal; Neuroprotect | 2018 |